These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21460407)

  • 1. Effects of aldosterone and mineralocorticoid receptor antagonism on cardiac ion channels in the view of upstream therapy of atrial fibrillation.
    Laszlo R; Bentz K; Schreieck J
    Gen Physiol Biophys; 2011 Mar; 30(1):11-9. PubMed ID: 21460407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation.
    Tsai CT; Chiang FT; Tseng CD; Hwang JJ; Kuo KT; Wu CK; Yu CC; Wang YC; Lai LP; Lin JL
    J Am Coll Cardiol; 2010 Feb; 55(8):758-70. PubMed ID: 20170814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits.
    Laszlo R; Bentz K; Konior A; Eick C; Schreiner B; Kettering K; Schreieck J
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Oct; 382(4):347-56. PubMed ID: 20799026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin treatment affects atrial ion currents and their tachycardia-induced remodeling in rabbits.
    Laszlo R; Menzel KA; Bentz K; Schreiner B; Kettering K; Eick C; Schreieck J
    Life Sci; 2010 Oct; 87(15-16):507-13. PubMed ID: 20851131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS; Morillo CA; Connolly SJ
    Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillation and renin-angiotensin system.
    Serra JL; Bendersky M
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):215-23. PubMed ID: 19124423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial fibrillation and atrial fibrosis.
    Tan AY; Zimetbaum P
    J Cardiovasc Pharmacol; 2011 Jun; 57(6):625-9. PubMed ID: 21633248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biology of the substrate of atrial fibrillation].
    Hatem S
    Biol Aujourdhui; 2012; 206(1):5-9. PubMed ID: 22463991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Morphological remodeling in atrial fibrillation].
    Goette A; Lendeckel U
    Herz; 2006 Apr; 31(2):101-7; quiz 142-3. PubMed ID: 16738831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation.
    Gaborit N; Steenman M; Lamirault G; Le Meur N; Le Bouter S; Lande G; Léger J; Charpentier F; Christ T; Dobrev D; Escande D; Nattel S; Demolombe S
    Circulation; 2005 Jul; 112(4):471-81. PubMed ID: 16027256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation.
    Greiser M; Neuberger HR; Harks E; El-Armouche A; Boknik P; de Haan S; Verheyen F; Verheule S; Schmitz W; Ravens U; Nattel S; Allessie MA; Dobrev D; Schotten U
    J Mol Cell Cardiol; 2009 Mar; 46(3):385-94. PubMed ID: 19100271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrical remodeling in atrial fibrillation.
    Dobrev D
    Herz; 2006 Apr; 31(2):108-12; quiz 142-3. PubMed ID: 16738832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of up-regulation of IK1 in action potential shortening associated with atrial fibrillation in humans.
    Zhang H; Garratt CJ; Zhu J; Holden AV
    Cardiovasc Res; 2005 Jun; 66(3):493-502. PubMed ID: 15914114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac ion channels and mechanisms for protection against atrial fibrillation.
    Grunnet M; Bentzen BH; Sørensen US; Diness JG
    Rev Physiol Biochem Pharmacol; 2012; 162():1-58. PubMed ID: 21987061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats.
    Kimura S; Ito M; Tomita M; Hoyano M; Obata H; Ding L; Chinushi M; Hanawa H; Kodama M; Aizawa Y
    Hypertens Res; 2011 May; 34(5):584-91. PubMed ID: 21248754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New pharmacological targets and treatments for atrial fibrillation.
    Carlsson L; Duker G; Jacobson I
    Trends Pharmacol Sci; 2010 Aug; 31(8):364-71. PubMed ID: 20605645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial structural remodeling as an antiarrhythmic target.
    Burstein B; Nattel S
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):4-10. PubMed ID: 18594481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial ionic remodeling induced by atrial tachycardia in the presence of congestive heart failure.
    Cha TJ; Ehrlich JR; Zhang L; Nattel S
    Circulation; 2004 Sep; 110(12):1520-6. PubMed ID: 15381657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation.
    Korantzopoulos P; Kolettis TM; Galaris D; Goudevenos JA
    Int J Cardiol; 2007 Feb; 115(2):135-43. PubMed ID: 16764958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.